Adimab Announces New Discovery Collaboration with Kyowa Hakko Kirin

  Adimab Announces New Discovery Collaboration with Kyowa Hakko Kirin

   -Receives Milestone Payments from Existing Partners Biogen Idec, Gilead
                         Sciences, and Novo Nordisk-

Business Wire

LEBANON, N.H. -- January 7, 2013

Adimab, LLC, a technology leader in the discovery of fully human antibodies,
today announced a two-target funded discovery collaboration with Kyowa Hakko
Kirin (KHK) of Tokyo, Japan. Based on the strength and flexibility of Adimab’s
platform, KHK has designated a membrane protein target as the initial
collaboration target. In addition, Adimab announced the receipt of milestone
payments from its existing collaborations with Gilead, Biogen Idec and Novo
Nordisk.

“We are pleased to announce another major pharma partnership,” said Tillman
Gerngross, CEO and co-founder of Adimab. “While other technology companies
have diverted their focus by developing an internal pipeline of therapeutic
products, we have committed all our resources to offering our customers the
best discovery technology in the industry.”

Adimab and KHK have entered into a collaboration whereby Adimab will use its
proprietary discovery and optimization platform to identify fully human
antibodies against two targets selected by KHK. For each target, the agreement
grants KHK the right to research antibodies generated from the collaboration
for potential use as therapeutic products. Under the terms of the agreement,
Adimab will receive various upfront fees including research fees and technical
milestones. In addition, for each target, KHK will have the sole option to
exclusively license antibodies from the collaboration, and if KHK were to
exercise the option for a particular target, then Adimab would receive license
fees, clinical milestones and royalties on therapeutic product sales for such
target.

In addition, Adimab announced the achievement of technical milestones from its
ongoing collaborations with Biogen Idec, Gilead, and Novo Nordisk.

“Adimab continues to see significant interest in our platform from new
companies, and this is directly related to the success we have had in our
existing partnerships,” said Guy Van Meter, Vice President of Business
Development at Adimab. “Speed is always a factor in antibody discovery, but
the ability to consistently deliver where other technologies have failed is
just as important. Fortunately, we can do both.”

Over the past three and a half years, Adimab has established collaborations
with multiple leading pharmaceutical companies, including Merck, Roche,
Novartis, Pfizer, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead and
Kyowa Hakko Kirin.

About Adimab

Adimab’s integrated antibody discovery and optimization platform provides
unprecedented speed from antigen to purified, full-length human IgGs. Adimab
offers fundamental advantages by delivering diverse panels of therapeutically
relevant antibodies that meet the most aggressive standards for affinity,
epitope coverage, species cross-reactivity and developability. Adimab enables
its partners to rapidly expand their biologics pipelines through a broad
spectrum of technology access arrangements. For more information, visit
http://www.adimab.com.

Contact:

MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
Chris@macbiocom.com
 
Press spacebar to pause and continue. Press esc to stop.